Lexicon Pharmaceuticals (LXRX) Stock Rockets On Positive Data

Lexicon Pharmaceuticals LXRX Stock News

Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) stock is making a run for the top in the market this morning, and for good reason. The company released positive Phase 3 data surrounding a diabetees treatment. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

LXRX Stock Rockets On Positive Data

In the press release, Lexicon Pharmaceuticals provided data from four Phase 3 clinical studies. The studies assessed sotagliflozin in patients with Type 2 diabetes. The company said that the final results of the studies will be preserved for upcoming medical congresses and publications.

Read more at Alpha Stock News!


Please enter your comment!
Please enter your name here